Skip to Content

10 reasons the PD-L1 biomarker is transforming tumour testing

Learn why the VENTANA PD-L1 (SP263) Assay is transforming the way we diagnose cancer
March 24, 2025 by
Bio Synergy

Start writing here...

Read Next
Five reasons why our HER2 (4B5) assay continues to be the trusted diagnostic assay of choice
Roche’s portfolio of immunohistochemistry (IHC) and in situ hybridization (ISH) breast cancer diagnostic assays provide high sensitivity, specificity and consistency